News & Events

Press Releases

Frequency Therapeutics Announces Appointment of Glenn Dubin to

Board of Directors

WOBURN, Mass., April 4, 2019 – Frequency Therapeutics, a clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), today announced the addition of Glenn Dubin to the Company’s Board of Directors. Mr. Dubin, the Principal of Dubin & Co. LP, a private investment company based in New York, brings three decades of experience leading global, multi-strategy organizations across a wide range of industries to Frequency’s Board.

“We are thrilled to welcome Glenn to the Board during this auspicious time in Frequency’s growth and development,” said Marc Cohen, Frequency’s Executive Chairman. “Glenn brings broad leadership experience across a wide variety of industry verticals and will be tremendously valuable for us as our clinical pipeline and business opportunities continue to mature.”

Mr. Dubin co-founded Highbridge Capital Management LLC, an alternative asset management company in 1992. In 2009, Highbridge was acquired by JP Morgan Asset Management, and Mr. Dubin remained at the helm to oversee the transition – a transition considered by many to be an example of a model succession plan. In 2012, Mr. Dubin, along with a prominent group of investors, acquired Castleton Commodities International LLC (formerly Louis Dreyfus Highbridge Energy), a global merchant energy company active in the physical and financial commodity markets and infrastructure investing. In 2013, Mr. Dubin stepped down as Chairman and CEO of Highbridge to focus on Dubin & Co. and the founding of Engineers Gate LP, a proprietary quantitative trading company. Engineers Gate has committed itself to building a next generation operating and technology platform for systematic trading strategies across global liquid markets.

“I am delighted to join the Frequency team and am looking forward to playing an active role in the further development and expansion of Frequency’s business operations,” said Mr. Dubin. “Frequency’s PCA Regeneration technology is truly unique and is poised to make waves across a multitude of disease indications.”

Mr. Dubin is a founding Board member and former Board Chair of The Robin Hood Foundation. Since its inception in 1988, Robin Hood has made more than $2 billion in grants to the most effective poverty-fighting organizations in New York City by applying investment principles to charitable giving. He is also a trustee of Mount Sinai Medical Center in New York, a Board member of the Museum of Modern Art, and is a member of the Dean’s Executive Committee of the Harvard Kennedy School. He holds a B.A. in economics from the State University of New York at Stony Brook.

“Frequency continues to bring together world-renowned executives with extensive expertise in business development,” said David Lucchino, President, Co-founder and CEO of Frequency. “The addition of Glenn to our Board will provide sound guidance and deep knowledge to our executive leadership as we explore new therapeutic and business opportunities.”


Founded by pioneers in the field of regenerative medicine and drug delivery technology, Frequency’s Progenitor Cell Activation (PCA) Regeneration platform uses a combination of small molecules to stimulate progenitor cells within the body to repair diseased or damaged tissue. This technology enables native tissue regeneration without modifying genes or removing cells from the body. This avoids the potential safety risks of genetic engineering and the manufacturing challenges of traditional cell therapy. This approach has been validated both in animal and human cell models as well as in a human clinical trial with the potential for broad application across many therapeutic areas.

Frequency Therapeutics develops small molecule drugs to stimulate cells in the body to reverse biological deficits and restore healthy tissue. Through the transitory activation of these cells, Frequency enables disease modification without the complexity of genetic engineering. Our ground-breaking therapy uses a proprietary combination of small-molecule drugs that induce progenitor cells to multiply and create new cells. While Frequency’s lead program targets hearing restoration, our PCA Regeneration platform has the potential to touch upon a wide breadth of disease indications.

# # #

Media Inquiries:
Stefanie Tuck or Kari Watson
MacDougall Biomedical Communications
+1 781-235-3060